SEC Form 4 · accession 0001209191-18-012782
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. DesJardin
Officer — EVP, Technical Operations
Period of report
Feb 21, 2018
Accepted (ET)
Feb 22, 2018 · 9:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 21, 2018 | M | 2,181 | — | A | 6,269 | D | |
| Ordinary SharesF2 | Feb 21, 2018 | F | 891 | $14.09 | D | 5,378 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Feb 21, 2018 | M | 2,181 | D | — | — | Ordinary Shares | 2,181 | 6,545 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Reflects the net settlement of ordinary shares of the Issuer in connection with the vesting of restricted stock units.
- F3On February 21, 2017, the reporting person was granted 8,726 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.